Client News

Roquefort Therapeutics PLC – Director/PDMR Shareholding
Home / Client News / Roquefort Therapeutics PLC – Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Dr Simon Sinclair, Non-Executive Director has purchased ordinary shares in the Company, as detailed below:


Number of Ordinary Shares

Average Price Paid Per Share

Total Consideration Paid


6.93 pence



Following the above purchase of shares, Dr Simon Sinclair holds an interest in 96,336 Company ordinary shares and 300,000 warrants.


Director/PDMR Shareholding – 14:41:29 26 Jun 2023 – ROQ News article | London Stock Exchange


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This